BLAINJECTIONINJECTABLEPriority Review
Approved
Apr 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 5h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IMAAVY (nipocalimab-aahu) is a human IgG1 monoclonal antibody that binds to the neonatal Fc receptor (FcRn), reducing circulating IgG levels. It is approved for generalized myasthenia gravis (gMG) in anti-MuSK antibody-positive adults and warm autoimmune hemolytic anemia (wAIHA) in previously corticosteroid-treated adults. This mechanism targets the underlying autoimmune pathology by clearing pathogenic antibodies.
Growth
IMAAVY launches into niche autoimmune indications with moderate competitive pressure (30%), suggesting focused commercial teams focused on specialist penetration in neurology and hematology.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Johnson & Johnson is hiring 2 roles related to this product
Worked on IMAAVY at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.